Contract

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

“Many of our customers have been excited about it and decided to go that way. We just feel like, as gummies sort of take all the press, we might as well do our little part to say, ‘hey, look, there is a different way,’” says Terry Coyle, Vitaquest’s chief innovation officer.